Internal Medicine: Pulmonary Vascular Diseases

Internal Medicine · Clinical Specialties

How it begins

Comprehensive analysis of the vascular pathology of the lung: from the pathophysiology of the pulmonary vascular bed to the hemodynamic diagnosis, the updated classifications (Nice 2022) and the latest generation therapeutic algorithms in pulmonary hypertension, pulmonary thromboembolism and vasculitis.

What it covers

1. Physiology of Pulmonary Circulation
2. · 1.1 Normal Hemodynamic Parameters
3. · 1.2 Regulation of Pulmonary Vasomotor Tone
4. · 1.3 Response of the Right Ventricle to Pressure Overload
5. Classification of Pulmonary Hypertension (Nice 2022)
6. Pathogenesis of Pulmonary Arterial Hypertension (PAH)
7. · 3.1 Genetic and Molecular Base
8. · 3.2 The "Multiple Hit Model"
9. · 3.3 Histological Lesions of Vascular Remodeling
10. Diagnosis of PAH: Algorithm and Key Tests
11. · 4.1 Clinical Presentation
12. · 4.2 Stepwise Diagnostic Algorithm
13. Risk Stratification in PAH
14. · 5.1 Stratification Parameters
15. Treatment of PAH: Stepped Algorithm and Specific Drugs
16. · 6.1 General Measures
17. · 6.2 Specific Therapeutic Targets — The Three Ways
18. · 6.3 Pharmacology of Specific Agents
19. · 6.4 Initial Combination and Therapeutic Escalation Algorithm (ESC/ERS 2022)
20. · 6.5 Lung Transplant in PAH
21. · 6.6 New Therapeutic Targets under Investigation
22. HP Groups 2-5: Differential Characteristics and Management
23. · 7.1 Group 2: PH due to Left Heart Disease
24. · 7.2 Group 3: PH due to Pneumopathy and Chronic Hypoxia
25. · 7.3 Group 5: HP of Multifactorial Mechanisms
26. Pulmonary Thromboembolism (PTE): Diagnosis and Treatment
27. · 8.1 Pathophysiology of Acute PE
28. · 8.2 Risk Classification of Acute PE (ESC 2019)
29. · 8.3 Diagnosis of Acute PE
30. · 8.4 Treatment of PE
31. Chronic Thromboembolic HP (CTEPH) — Group 4
32. · 9.1 Diagnosis of CTEPH
33. · 9.2 Treatment of CTEPH
34. Pulmonary Vasculitis
35. · 10.1 Small Vessel Vasculitis Associated with ANCA
36. · 10.2 Goodpasture Syndrome (Anti-GBM Disease)
37. Pulmonary Arteriovenous Malformations (PAVMs) and Hereditary Hemorrhagic Telangiectasia (HHT)
38. · 11.1 Pathophysiological consequences of PAVMs
39. · 11.2 Diagnosis
40. · 11.3 Treatment of PAVMs
41. Cor Pulmonale
42. Special Syndromes: Portopulmonary Hypertension and Hepatopulmonary Syndrome
43. · 13.1 Portopulmonary Hypertension (PPH)
44. · 13.2 Hepatopulmonary Syndrome (HPS)
45. · 13.3 PVOD and Pulmonary Capillary Hemangiomatosis (PCH)